title: Gallstone recurrence after direct contact dissolution with methyl tert-butyl ether.
abstract: To determine the rate and characteristics of gallstone recurrence after direct contact dissolution with methyl tert-butyl ether, 60 consecutive patients were followed for up to 4.5 years (median 2.2 years) after complete disappearance of all stone residues and debris and cessation of adjuvant bile acid therapy. Initial gallstones had been multiple in all but four patients. Twenty-eight of the 60 patients developed recurrent gallstones. The cumulative risk of gallstone recurrence (actuarial analysis) was 23 +/- 6%, 34 +/- 7%, 55 +/- 8%, and 70 +/- 9% at one, two, three, and four years, respectively. The recurrent stones were usually multiple and small (6 +/- 4 mm). Gallstone recurrence was associated with recurrent biliary pain in two patients, one of whom developed acute cholecystitis. Recurrent stones were cleared completely by bile acid medication with or without shock-wave lithotripsy in 61 +/- 15% of patients at one year (actuarial analysis). In conclusion, gallstone recurrence after successful contact dissolution of multiple stones with methyl tert-butyl ether has to be expected in a high percentage of patients. Most patients, however, remain free of biliary pain during long-term follow-up.
authors.affiliation: Department of Medicine II, Klinikum Grosshadern, University of Munich, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Pauletzki
authors.forename: J
authors.initials: J
authors.lastname: Holl
authors.forename: M
authors.initials: M
authors.lastname: Sackmann
authors.forename: M
authors.initials: M
authors.lastname: Neubrand
authors.forename: U
authors.initials: U
authors.lastname: Klueppelberg
authors.forename: T
authors.initials: T
authors.lastname: Sauerbruch
authors.forename: G
authors.initials: G
authors.lastname: Paumgartner
mesh_terms: D000206:Actuarial Analysis; D002769:Cholelithiasis / Q000628:therapy*; D015331:Cohort Studies; D004987:Ethers / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008096:Lithotripsy; D008297:Male; D008738:Methyl Ethers; D008875:Middle Aged; D011446:Prospective Studies; D012008:Recurrence; D012307:Risk Factors; D012997:Solvents / Q000008:administration & dosage
chemical_list: D004987:Ethers; D008738:Methyl Ethers; D012997:Solvents; C043243:methyl tert-butyl ether